Premium
Identification of a SART‐1‐derived peptide capable of inducing HLA‐A24‐restricted and tumor‐specific cytotoxic T lymphocytes
Author(s) -
Kikuchi Megumi,
Nakao Masanobu,
Inoue Yoshiko,
Matsunaga Kazuko,
Shichijo Shigeki,
Yamana Hideaki,
Itoh Kyogo
Publication year - 1999
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/(sici)1097-0215(19990505)81:3<459::aid-ijc21>3.0.co;2-6
Subject(s) - ctl* , cytotoxic t cell , human leukocyte antigen , immunology , cancer immunotherapy , biology , peripheral blood mononuclear cell , peptide , immunotherapy , antigen , in vitro , immune system , cancer research , genetics , biochemistry
We have described the SART‐1 gene–encoding peptides recognized by HLA‐A2601‐restricted and tumor‐specific cytotoxic T lymphocytes (CTLs). We now have investigated whether SART‐1 encodes peptides capable of inducing the HLA‐A24‐restricted CTLs. Among the 18 different peptides with HLA‐A24‐binding motifs, the SART‐1 690 – 698 peptide (EYRGFTQDF) was most strongly recognized by the HLA‐A24‐restricted and tumor‐specific CTLs established from an esophageal cancer patient. After a third stimulation in vitro, this peptide induced HLA‐A24‐restricted CTLs recognizing the SART‐1 259 + tumor cells in PBMCs of all HLA‐A24 homozygous and the majority of HLA‐A24 heterozygous cancer patients and healthy donors tested. A similar activity, induction of CTLs from PBMCs, was observed in the Saccharomyces cerevisiae –derived nonapeptide (EYRGFTPMF) that shares 7 amino acids with the SART‐1 690 – 698 peptide. The SART‐1 690 – 698 peptide–induced CTL activity was significantly higher in PBMCs of HLA‐A24 homozygotes than in HLA‐A24 heterozygotes. The CTL precursor frequency in PBMCs after a third stimulation in vitro with the SART‐1 690 – 698 peptide was high (>1/200) in both cancer patients and healthy donors. The SART‐1 690 – 698 peptide could thus be useful for specific immunotherapy of HLA‐A24 + cancer patients. Int. J. Cancer 81:459–466, 1999. © 1999 Wiley‐Liss, Inc.